Biopharm GmbH has signed an agreement with Merck Serono to research the molecular engineering of a biologic compound for the treatment of osteoarthritis. The two companies will enter a joint discovery project focusing on a potential pro-anabolic osteoarthritis modifying drug based on a growth factor derived from the Biopharm platform technology. Payment fees include an upfront payment, service fees, potential milestone, and royalty payments. Further financial details were not disclosed.   The re...